N/A
Completed N=148
Nexplanon Application Post-Abortion (NAPA)
Contraception · Abortion, Therapeutic
Source: ClinicalTrials.gov NCT02037919 ↗
Enrolled (actual)
148
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Intention-to-treat Analysis of Etonogestrel Implant Use — 40; 19; 3; 3 Participants
Summary
Women who receive Nexplanon immediately post abortion will be significantly more likely to be using the device 6 months after the procedure than those assigned to receive the device 2-4 weeks after the procedure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intention-to-treat Analysis of Etonogestrel Implant Use |
40; 19; 3; 3 | — |
| PRIMARY Per-protocol Analysis of Etonogestrel Implant Use |
40; 19; 3; 3; 0; 8 | — |
| SECONDARY Repeat Pregnancy |
1; 1; 42; 29 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age and older,
- an intrauterine pregnancy > 14 weeks and <23 6/7 weeks gestation and desire termination of pregnancy
- desire a Nexplanon for contraception
- able to give informed consent in English
- no contraindications to Nexplanon (based on U.S. CDC Medical Eligibility Criteria for Contraception) or D&E
Exclusion Criteria
- unable to give informed consent
- have any of the following medical conditions: active venous thromboembolism, known or suspected sex-steroid sensitive malignancies, current hepatic disease with abnormal liver function tests, undiagnosed vaginal bleeding, hypersensitivity to any of the ingredients in Nexplanon.
- non-surgical management of pregnancy
- prior participation in this study
- breast cancer or a history of breast cancer
Data sourced from ClinicalTrials.gov (NCT02037919). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.